Company
Bristol Myers Squibb
1,901 Legal Matters
89
936
876

Bristol Myers Squibb Company IP Overview

Practice Areas
Recent StatisticsView All
Subscription-Only
View Concierge Program
PatentsView All
Patents Issued Each Year
TrademarksView All
Trademark Applications Filed Each Year
LitigationView All
Cases Filed Each Year
Pedram Sameni
Patexia Insight 218: A Deep Dive into the Top Pharmaceutical Companies in ANDA Litigation
Pedram Sameni
Sep 12, 2024
In the pharmaceutical industry, innovation drives progress, but intense legal battles, particularly in ANDA (Abbreviated New Drug Application) litigation, shape... Read More
Pedram Sameni
Patexia Insight 213: The Revlimid Dispute From Antitrust Battles to Patent Litigation
Pedram Sameni
Jul 25, 2024
Revlimid (lenalidomide), developed by Celgene Corporation, has been a groundbreaking treatment for multiple myeloma, myelodysplastic syndromes, and mantle cell lymphoma... Read More
Mikele Bicolli
Top 10 Pharmaceuticals Losing Exclusivity in the US in 2024
Mikele Bicolli
Mar 11, 2024
As the relentless march of time continues, pharmaceutical executives find themselves facing the inevitability of patent expirations and the subsequent... Read More
Practice Areas
PatentsView All
Patents Issued Each Year
LitigationView All
Cases Filed Each Year
Recent StatisticsView All
Subscription-Only
View Concierge Program
TrademarksView All
Trademark Applications Filed Each Year
Pedram Sameni
Patexia Insight 218: A Deep Dive into the Top Pharmaceutical Companies in ANDA Litigation
Pedram Sameni
Sep 12, 2024
In the pharmaceutical industry, innovation drives progress, but intense legal battles, particularly in ANDA (Abbreviated New Drug Application) litigation, shape... Read More
Pedram Sameni
Patexia Insight 213: The Revlimid Dispute From Antitrust Battles to Patent Litigation
Pedram Sameni
Jul 25, 2024
Revlimid (lenalidomide), developed by Celgene Corporation, has been a groundbreaking treatment for multiple myeloma, myelodysplastic syndromes, and mantle cell lymphoma... Read More
Mikele Bicolli
Top 10 Pharmaceuticals Losing Exclusivity in the US in 2024
Mikele Bicolli
Mar 11, 2024
As the relentless march of time continues, pharmaceutical executives find themselves facing the inevitability of patent expirations and the subsequent... Read More